Development of a gum base formulation for Nystatin (cas 1400-61-9); a new drug delivery approach for treatment of oral candidiasis

Add time:09/04/2019    Source:sciencedirect.com

The purpose of this work is to develop a new formulation of nystatin using chewing gum as a drug delivery system to optimize the drug release rate in order to improve the desired efficacy in the site of action for treating patients with oral candidiasis. Medical chewing gum is a pleasant and highly convenient method of administration for almost all groups of patients. Nystatin is an antifungal drug with very low solubility in water. When the drug was formulated alone in chewing gum, its release rate was very low. To increase its aqueous solubility and release rate from the chewing gum, polyethylene glycol 4000 and 400 were used as solubilizing agents. Nystatin formulations were prepared as a solid dispersion with PEG-4000 and simple dispersion with PEG-400 and incorporated into the chewing gum. The results of the solubility studies with shake-flask method indicated that the apparent solubility of nystatin increased significantly up to 4.3 mg/ml and 2.6 mg/ml with PEG-4000 and PEG-400 respectively in phosphate buffer pH 6.8. In vitro dissolution studies were performed by a mastication device, demonstrating that the nystatin-PEG4000 solid dispersion formulation through the chewing gum had extended and complete release rate. The results obtained here suggested that the nystatin chewing gum was more efficacious than the commercial nystatin suspension, and the optimized formulation had also good stability.

We also recommend Trading Suppliers and Manufacturers of Nystatin (cas 1400-61-9). Pls Click Website Link as below: cas 1400-61-9 suppliers

Prev:Stability and efficacy of combined Nystatin (cas 1400-61-9) and chlorhexidine against suspensions and biofilms of Candida albicans
Next:Original Research ArticleEvaluation of mucoadhesive oral films containing Nystatin (cas 1400-61-9))